ES2196251T3 - Agente terapeutico para el tratamiento de dermatitis canina rebelde. - Google Patents

Agente terapeutico para el tratamiento de dermatitis canina rebelde.

Info

Publication number
ES2196251T3
ES2196251T3 ES97122864T ES97122864T ES2196251T3 ES 2196251 T3 ES2196251 T3 ES 2196251T3 ES 97122864 T ES97122864 T ES 97122864T ES 97122864 T ES97122864 T ES 97122864T ES 2196251 T3 ES2196251 T3 ES 2196251T3
Authority
ES
Spain
Prior art keywords
canine
dermatitis
therapeutic agent
rebel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97122864T
Other languages
English (en)
Inventor
Tomiya Uchino
Katsushige Yamada
Fumiyoshi Okano
Masahirro Satoh
Isao Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2196251T3 publication Critical patent/ES2196251T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION ES UN AGENTE TERAPEUTICO COMPUESTO POR INTERFERON GA CANINO, PARA LA DERMATITIS CANINA INTRATABLE.
ES97122864T 1997-03-06 1997-12-24 Agente terapeutico para el tratamiento de dermatitis canina rebelde. Expired - Lifetime ES2196251T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5161297 1997-03-06

Publications (1)

Publication Number Publication Date
ES2196251T3 true ES2196251T3 (es) 2003-12-16

Family

ID=12891734

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97122864T Expired - Lifetime ES2196251T3 (es) 1997-03-06 1997-12-24 Agente terapeutico para el tratamiento de dermatitis canina rebelde.

Country Status (9)

Country Link
US (1) US5955069A (es)
EP (1) EP0862918B1 (es)
KR (1) KR100530125B1 (es)
AU (1) AU734887B2 (es)
CA (1) CA2219275C (es)
DE (1) DE69720410T2 (es)
ES (1) ES2196251T3 (es)
NZ (1) NZ329461A (es)
ZA (1) ZA9711660B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197292B1 (en) * 1997-03-06 2001-03-06 Toray Industries, Inc. Therapeutic agent and treatment for canine intractable dermatitis
AU734887B2 (en) * 1997-03-06 2001-06-28 Toray Industries, Inc. Therapeutic agent and treatment for canine intractable dermatitis
EP0950663B1 (en) * 1997-08-01 2007-11-07 Toray Industries, Inc. Method for stabilizing useful proteins and useful protein compositions
CA2511209A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Agent for treatment of pemphigoid
CN107383207A (zh) * 2017-08-09 2017-11-24 芜湖英特菲尔生物制品产业研究院有限公司 一种重组犬长效干扰素α及制备此长效干扰素的融合蛋白及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE121945T1 (de) * 1989-12-01 1995-05-15 Childrens Medical Center Verwendung von gamma-interferon zur herstellung eines medikaments für die behandlung von steroid- abhängigem asthma.
JPH09234085A (ja) * 1995-12-28 1997-09-09 Toray Ind Inc イヌインターフェロンγの製造法
AU734887B2 (en) * 1997-03-06 2001-06-28 Toray Industries, Inc. Therapeutic agent and treatment for canine intractable dermatitis

Also Published As

Publication number Publication date
CA2219275A1 (en) 1998-09-06
DE69720410D1 (de) 2003-05-08
CA2219275C (en) 2011-08-02
AU734887B2 (en) 2001-06-28
AU4840697A (en) 1998-09-10
KR19980079554A (ko) 1998-11-25
EP0862918A3 (en) 2000-02-23
US5955069A (en) 1999-09-21
KR100530125B1 (ko) 2006-04-17
EP0862918A2 (en) 1998-09-09
NZ329461A (en) 1999-05-28
EP0862918B1 (en) 2003-04-02
ZA9711660B (en) 1998-06-25
DE69720410T2 (de) 2003-11-27

Similar Documents

Publication Publication Date Title
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
MX9302618A (es) Antagonistas de endotelina de fenil sulfonamidas.
ES2164182T3 (es) Benzociclopentanoxazolidinonas que contienen heteroatomos con actividad antibacteriana.
PT871730E (pt) Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
ES2148582T3 (es) Fungicidas para la represion de la enfermedad de mal de pie de plantas.
ES526102A0 (es) Mejoras introducidas en el objeto de la patente de invencion principal n 518.044 por: mejoras en la fabricacion de municion, preferentemente para el empleo contra objetivos cubiertos
ES2304795T3 (es) Anticuerpos agonistas para el receptor de trombopoyetina y sus usos terapeuticos.
ES2159977T3 (es) Esteres de (met)acrilato de organosiloxano-polioles, proceso para su preparacion y su empleo como composiciones de revestimiento susceptibles de curado por radiacion.
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
GT199800037A (es) Combinaciones para diabetes de sulfonilurea - glitazona.
ES2188795T3 (es) Agentes antimicrobianos benzoxacina.
PT1156043E (pt) Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
HN1998000124A (es) Terapia de combinacion
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
ES2067154T3 (es) Dibenzoilalquilcianohidracinas.
HN1998000088A (es) Tratamiento de resistencia a la insulina
MX9601368A (es) Metodo de tratamiento de la reestenosis por terapia genica.
PA8587801A1 (es) Isomeros posicionales de interferon alfa 2-a monopegilado
AU1558197A (en) Preventives and remedies for thrombocytopenia
ES2135254T3 (es) Procedimiento para la degradacion de quinolonas y naftiridonas.
MX9301926A (es) Peptidos con modificaciones en el n-terminal.
BR0210632A (pt) Tratamento de doença parasìtica
BR0017168A (pt) Piranoindóis para tratamento de glaucoma